期刊文献+

钙拮抗剂拉西地平的合成新工艺 被引量:4

New synthetic route for lacidipine
下载PDF
导出
摘要 目的完成钙拮抗剂拉西地平合成的新工艺。方法以邻苯二甲醛、β 氨基巴豆酸乙酯、三苯基亚膦基乙酸叔丁酯为原料 ,采用常规的化学合成法合成。结果采用先形成二氢吡啶环 ,再通过Wittig反应制备烯烃双键的顺序 ,拓展了拉西地平合成的新工艺。 结论新工艺与专利文献相比 ,具有收率高、操作简便的特点 ,更适于工业化生产。 Aim To establish a new method for the synthesis of lacidipine.Method To form the 1,4 dihydropyridine ring at first and to construct the double bond of the acrylic ester side chain,exploiting phthalaldehyde,ethyl 3 aminocrotonate and diethyl t butoxycarbonylmethyl phosphonate as the starting materials.Lacidipine was prepared through the new strategy.Results and conclusion Lacidipine was synthesized in a good yield through a 2 step procedure.It is different from the patent synthetic procedure for lacidipine and it is a new synthetic procedure with better yield and would be suitable for industrial manufacture.
出处 《中国药物化学杂志》 CAS CSCD 2004年第6期365-367,共3页 Chinese Journal of Medicinal Chemistry
关键词 药物化学 工艺改进 化学合成 钙拮抗剂 拉西地平 medicinal chemistry process improvement chemical synthesis calcium channel blocker 1,4-di-hydropyridine lacidipine
  • 相关文献

参考文献9

  • 1Cominachini L,Garbin U,Pasini AF,et al.Lacidipine inhibits the activation of the transcription factor NF-κB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells[J].J Hypertens,1997,15:1633-1639.
  • 2Triggle DJ,Langs DA,Janis RA.Ca2+ channels ligands:structure-function relationships of the 1,4-dihydropyridine[J].Med Res Rev,1989,9:123-180.
  • 3Borchard V.calcium antagonists in comparison:view of the pharmacologist[J].J Cardiovasc Pharmacol,1994,24(Suppl 2):85-91.
  • 4Semeraro C,Micheli D,Pieraccioli D,et al.1,4-Dihydropyridines[P].US:4801599,1989-01-31.
  • 5Singh BN,Collett JT,Chew CY.New perspectives in the pharmacological therapy of cardiac arrhythmia[J].Prog Cardiovasc Dis,1980,22:243-301.
  • 6Scheen AJ.Drug of the month.Lacidipine[J].Rev Med Liego,1994,49:163-164.
  • 7Lee CR,Bryson HB.Lacidipine,a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension[J].Drugs,1994,48:274-296.
  • 8Cominachini L,Pasini AF,Garbin U,et al.Antioxidant activity of different dihydropyridines[J].Biochem Biophys Res Commun,2003,302:679-684.
  • 9Cominachini L,Pasini AF,Pastorino AM,et al.Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-α on endothelial cells[J].J Hypertens,1999,17:1837-1841.

同被引文献22

  • 1吴超.中医药治疗缺血性心脏病的研究进展[J].内蒙古中医药,2009(2):92-93. 被引量:4
  • 2吴桂萍.拉西地平的研究进展[J].中国心血管病研究,2005,3(6):468-470. 被引量:9
  • 3张春暘.拉西地平的近年研究进展[J].国外医药(合成药.生化药.制剂分册),1996,17(5):289-291. 被引量:1
  • 4李乐.新型钙拮抗剂拉西地平的药理与临床应用[J].中国新药杂志,1997,6(3):182-184. 被引量:10
  • 5LeeCR, Bryson HB. Lacidipine, a review of its pharmacodynamic and pharmacokinetieproperties and therapeutic potential in the treatment of hypertension, Drugs, 1994,48:274-296.
  • 6Scheen AJ. Drug of the month, lacidipine. Rev Med Liego, 1994, 49 : 163-164.
  • 7Cominachini L, Garbin U, Pasini AF, et al. Lacidipine inhibits the activation of the transciption factor NF-kB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J Hypertens, 1997,15 : 1633-1639.
  • 8黄河清,李中军,王安邦,等.降高血压药拉西地平的合成工艺.中国,200410050176[P].2005-03.16.
  • 9卫生部药品标准[S].WS1-(X-061)-2013Z.
  • 10英国药典2014年版[S].2014:707-708.

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部